FDA: Prasugrel [Regulatives / Guidelines]

posted by intuitivepharma – India, 2013-12-20 08:36 (4566 d 18:05 ago) – Posting: # 12084
Views: 31,675

Dear Helmut,

How about this bioequivalence requirement [based on USFDA individual product bioequivalence recommendations] for Prasugrel Hydrochloride

Active ingredient: Prasugrel Hydrochloride

Analytes to measure (in appropriate biological fluid): Inactive metabolite R-95913 and active metabolite R-138727 in plasma.

Bioequivalence based on (90% CI): Inactive metabolite R-95913.

Please submit the data of active metabolite (R-138727) including individual and mean concentrations, individual and mean pharmacokinetic parameters, and geometric means and ratios of means for AUC and Cmax, as supportive evidence of comparable therapeutic outcome.

Can I justify my ANDA if test formulation is bioequivalent for the active metabolite (R-138727) and not bioequivalent for the Inactive metabolite R-95913? :confused:


Edit: Subject line changed. [Helmut]

Thanks & Regards,
IP.

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
141 visitors (0 registered, 141 guests [including 28 identified bots]).
Forum time: 03:42 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5